Please login to the form below

Not currently logged in


This page shows the latest Spritam news and features for those working in and with pharma, biotech and healthcare.

3D printed epilepsy drug launched in the US

3D printed epilepsy drug launched in the US

Aprecia’s Spritam is now available as a prescription drug. The first ever drug manufactured using 3D printing technology is now available to US patients with epilepsy. ... The 3D printing of Spritam enables it to be produced as a porous formulation

Latest news

  • Printable pharma Printable pharma

    The approval of Aprecia Pharmaceuticals' new epilepsy drug Spritam (levetiracetam) in August was a landmark because it marked the first time that 3D printing was deployed as an alternative production method ... Spritam is designed to fill a need for

  • FDA approves world’s first 3D printed drug FDA approves world’s first 3D printed drug

    The drug Spritam (levetiracetam), from Aprecia Pharmaceuticals, has been given the green light from the US regulator as an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and ... There are already a number of treatments

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...